Clinical trial · no report yet · Phase 2
CYTOSHRINK
SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
- NCT04090710 ↗
- Completed
- Ontario Clinical Oncology Group (OCOG)
- 32 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 21 | |
| YouTube | 5 | |
| Podcasts | 5 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Ipilimumab/ Nivolumab; SBRT + Ipilimumab/Nivolumab
- Arms
- Standard of Care I/N alone · Active comparator
- Standard of Care I/N plus primary disease SBRT · Experimental
- Enrollment
- 66
- Primary outcomes
- Progression free survival (PFS)
- Sponsor
- Ontario Clinical Oncology Group (OCOG) with Bristol-Myers Squibb, Hamilton Health Sciences Corporation
- Start
- Jan 29, 2020
- Primary completion
- Apr 23, 2026
- Results posted
- No
- Registry record
- NCT04090710 · updated Aug 28, 2026